Inspire Medical Q3 revenue $224.5M (+10% YoY); net income down; FY25 EPS guidance raised to $0.90-$1.00

Inspire Medical Systems, Inc.

2025-Q3 EPS reported $0.31 revenue$642,904,000

Revenue $224.5M in Q3 2025, up 10% from $203.2M a year ago; U.S. revenue $214.4M (+9%), OUS revenue $10.1M (+37%).
Gross margin 85.8% vs 84.1% YoY, driven by higher volume and Inspire V mix with lower COGS.
Net income $9.9M ($0.34 diluted EPS) vs $18.5M ($0.60) prior year; adjusted diluted EPS $0.38.
FY2025 revenue guidance reaffirmed $900M-$910M (12-13% growth); EPS guidance raised to $0.90-$1.00 from $0.40-$0.50.
Completed $50M in share repurchases; Q3 operating cash flow $68.5M; cash & investments $410.9M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.